Bitter-Tasting Drugs Can Control Appetite Hormones GDF15 and GLP-1 Through Taste Receptors in the Gut | Research

The takeaway

Bitter compounds regulate the satiety signals GDF15 and GLP-1 from gut epithelial cells through bitter taste receptors and motilin receptors, with genetic variations in taste receptors potentially predicting individual responses — opening a new avenue for obesity treatment.

GDF15 + GLP-1 dual regulation
bitter compounds control both satiety signals simultaneously through gut taste receptors, with TAS2R genetic polymorphisms predicting individual responsiveness

What the researchers found

Bitter compounds regulate GDF15 and GLP-1 release from human gut epithelial cells through specific TAS2R subtypes and the unfolded protein response, with TAS2R polymorphisms predicting therapeutic responsiveness.

Why it matters

This reveals a completely new mechanism for controlling appetite — bitter taste receptors in the gut that regulate two powerful satiety signals simultaneously. Since genetic variations predict who responds, this could enable personalized obesity treatment based on taste receptor genetics, offering an alternative to injectable GLP-1 drugs.

The numbers in context

GDF15 acts via GFRAL receptor in hindbrain; 25 TAS2R subtypes exist in gut; both TAS2Rs and motilin receptors mediate bitter compound effects.

How the study worked

Placebo-controlled, double-blind, randomized crossover study of oral hydroxychloroquine in healthy volunteers (plasma GDF15, ghrelin, hunger scores). Ex vivo stimulation of primary jejunal crypts from patients with obesity. Immunofluorescence colocalization. TAS2R antagonist (GIV3727) blocking studies. TAS2R4/43 genotyping for polymorphism analysis.

Who was studied

Intestinal tissue from patients with obesity

What this study cannot tell us

Small crossover study in healthy volunteers — larger obesity trials needed. Ex vivo gut tissue experiments may not fully reflect in vivo responses. The bitter compounds tested have other pharmacological effects beyond taste receptors. Not all bitter compounds had the same direction of effect on GDF15. Long-term efficacy and tolerability of bitter-based appetite suppression unknown.

How to read the evidence

Moderate — combines a controlled human study (small) with mechanistic ex vivo work from patient tissue. Novel findings with strong mechanistic support but limited clinical validation for obesity treatment.

When this study was published

Published in 2024, at the forefront of emerging research connecting taste receptor biology to metabolic disease treatment.

The bigger picture

This study connects three hot research areas: GLP-1 biology, GDF15 as a satiety signal, and taste receptor pharmacology. The finding that oral bitter compounds can boost both GDF15 and GLP-1 through gut taste receptors suggests a potential oral, non-peptide alternative to injectable GLP-1 agonists. The pharmacogenomic angle (taste receptor polymorphisms predicting response) adds a precision medicine dimension rarely seen in obesity research.

Questions still open

Could specific bitter compounds be developed as oral appetite suppressants that work through GDF15/GLP-1 without the side effects of existing bitter drugs?
What proportion of the population carries TAS2R polymorphisms that would make them good or poor responders to bitter-based obesity treatments?
Does chronic bitter compound exposure lead to taste receptor desensitization and loss of appetite-suppressing effect?

Common questions

Could bitter foods help with weight loss?

This study suggests that bitter compounds activate taste receptors in the gut that trigger release of satiety hormones GDF15 and GLP-1, potentially reducing hunger. However, the effect depends on which specific bitter compound is consumed and your individual genetics — some people's taste receptors respond more strongly than others. Research is still early, and we don't yet know if dietary bitter compounds provide enough stimulation for meaningful appetite suppression.

Why does azithromycin cause nausea — is it related to this?

The study found that azithromycin (a bitter-tasting antibiotic) triggers GDF15 release not through bitter taste receptors but through the motilin receptor in the gut. GDF15 is a stress-related satiety signal that can cause nausea at high levels. This explains why azithromycin commonly causes stomach upset and nausea — it's inadvertently activating a powerful appetite-suppressing and nausea-inducing pathway.

Read the original research

Bitter-tasting drugs tune GDF15 and GLP-1 expression via bitter taste or motilin receptors in the intestine of patients with obesity.

Molecular metabolism, 88, 102002

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Qian; Farhadipour, Mona; Thijs, Theo; Ruilova Sosoranga, Emily; Van der Schueren, Bart; Ceulemans, Laurens J; Deleus, Ellen; Lannoo, Matthias; Tack, Jan; Depoortere, Inge. (2024). Bitter-tasting drugs tune GDF15 and GLP-1 expression via bitter taste or motilin receptors in the intestine of patients with obesity.. Molecular metabolism, 88, 102002. https://doi.org/10.1016/j.molmet.2024.102002